A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03850535

Recruitment Status : Terminated (Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.)

First Posted : February 21, 2019

Last Update Posted : October 12, 2020

Sponsor:

Information provided by (Responsible Party):

Hoffmann-La Roche

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	September 10, 2020
Actual Study Completion Date :	September 10, 2020

To Top